19th Expert Committee: Expert reviews
A to E
-
Amphotericin (To be moved to core list) -- Adults and Children (Review No.1)
pdf, 104kb -
Anaesthetics (Review) -- Children (Review No.1)
pdf, 122kb -
Anaesthetics (Review) -- Children (Review No.2)
pdf, 92kb -
Antiarrhythmics (Review) -- Children (Review No.1)
pdf, 93kb -
Antiarrhythmics (Review) -- Children (Review No.2)
pdf, 151kb -
Antiparkinsonism medicines (Review) -- Adults (Review No.1)
pdf, 130kb -
Antiparkinsonism medicines (Review) -- Adults (Review No.2)
pdf, 188kb -
ANTIRETROVIRALS (abacavir, abacavir + lamivudine, atazanavir + ritonavir, tenofovir + lamivudine + efavirenz) (Review No.1)
pdf, 82kb -
ANTIRETROVIRALS (abacavir, atazanavir + ritonavir, tenofovir + lamivudine, tenofovir + lamivudine + efavirenz) -- Addition -- Adults (Review No.2)
pdf, 172kb -
ANTIRETROVIRALS (abacavir, efavirenz, lamivudine + nevirapine + zidovudine, lamivudine + stavudine, lamivudine + zidovudine, nevirapine) Addition -- Children (Review No.2)
pdf, 162kb -
Antiretrovirals (Formulations to be considered for possible deletion) -- Adults and Children (Review No.1)
pdf, 109kb -
Antiretrovirals (Formulations to be considered for possible deletion) -- Adults and Children (Review No.2)
pdf, 109kb -
Antiulcer medicines (Review) -- Adults (Review No.1)
pdf, 108kb -
Antiulcer medicines (Review) -- Adults (Review No.2)
pdf, 96kb -
Artesunate + mefloquine (Addition) -- Adults and Children (Review No.1)
pdf, 128kb -
Artesunate + mefloquine (Addition) -- Adults and Children (Review No.2)
pdf, 444kb -
Azithromycin (Addition) -- Adults and Children (Review No.1)
pdf, 100kb -
Azithromycin (Addition) -- Adults and Children (Review No.2)
pdf, 294kb -
Bedaquiline (Addition) -- Adults (Review No.1)
pdf, 96kb -
Bedaquiline (Addition) -- Adults (Review No.2)
pdf, 101kb -
Benznidazole (New formulation) -- Children (Review No.1)
pdf, 101kb -
Benznidazole (New formulation) -- Children (Review No.2)
pdf, 91kb -
Benzoyl peroxide (Review) -- Adults and Children (Review No.1)
pdf, 127kb -
Benzoyl peroxide (Review) -- Adults and Children (Review No.2)
pdf, 154kb -
Bevacizumab (Addition) -- Adults (Review No.1)
pdf, 104kb -
Bevacizumab (Addition) -- Adults (Review No.2)
pdf, 294kb -
Bevacizumab (Addition) -- Adults (Review No.3)
pdf, 150kb -
Calcium (Addition) -- Adults (Review No.1)
pdf, 169kb -
Calcium (Addition) -- Adults (Review No.2)
pdf, 449kb -
Chlorhexidine (New formulation) -- Children (Review No.1)
pdf, 93kb -
Chlorhexidine (New formulation) -- Children (Review No.2)
pdf, 136kb -
Chlorpromazine and haloperidol (Deletion) -- Children only (Review No.1)
pdf, 86kb -
Chlorpromazine and haloperidol (Deletion) -- Children only (Review No.2)
pdf, 299kb -
Clozapine (Addition as complementary medicine) -- Adults (Review No.1)
pdf, 91kb -
Clozapine (Addition as complementary medicine) -- Adults (Review No.2)
pdf, 307kb -
Coal tar (Review) -- Adults (Review No.1)
pdf, 172kb -
Coal tar (Review) -- Adults (Review No.2)
pdf, 162kb -
Colchicine (Re-instatement) -- Adults (Review No.1)
pdf, 141kb -
Colchicine -- Gout (Re-instatement) -- Adults (Review No.1)
pdf, 131kb -
Colchicine (Re-instatement) -- Adults (Review No.2)
pdf, 442kb -
Colloids -- Dengue (Review) -- Children (Review No.2)
pdf, 125kb -
Colloids -- Trauma (Review) -- Children (Review No.2)
pdf, 103kb -
Dexamethasone (New indication) -- Children (Review No.1)
pdf, 91kb -
Dexamethasone (New indication) -- Children (Review No.2)
pdf, 111kb -
Dithranol (Deletion) -- Adults (Review No.1)
pdf, 169kb -
Dithranol (Deletion) -- Adults (Review No.2)
pdf, 118kb -
Ear, nose and throat (Review) -- Adults and Children (Review No.1)
pdf, 77kb -
Ear, nose and throat (Review) -- Adults and Children (Review No.2)
pdf, 283kb -
Efavirenz (New formulation) -- Children (Review No.1)
pdf, 448kb
F to I
-
Ferrous salt + folic acid (New formulation) -- Adults (Review No.1)
pdf, 532kb -
Ferrous salt + folic acid (New formulation) -- Adults (Review No.2)
pdf, 136kb -
Ferrous salt + folic acid (New formulation) -- Adults (Review No.3)
pdf, 96kb -
Fixed-dose combination for secondary prevention of cardiovascular disease (Addition) -- Adults (Review No.1)
pdf, 314kb -
Fixed-dose combination for secondary prevention of cardiovascular disease (Addition) -- Adults (Review No.2)
pdf, 94kb -
Flucytosine (To be moved to core list) -- Adults and Children (Review No.1)
pdf, 94kb -
Flucytosine (To be moved to core list) -- Adults and Children (Review No.2)
pdf, 104kb -
Fluoxetine (Change to age restriction/Deletion from EMLc) -- Adults and Children (Review No.1)
pdf, 128kb -
Fluoxetine (Change to age restriction/Deletion from EMLc) -- Adults and Children (Review No.2)
pdf, 105kb -
Fomepizole (Addition) -- Adults and Children (Review No.1)
pdf, 121kb -
Fomepizole (Addition) -- Adults and Children (Review No.2)
pdf, 107kb -
Glibenclamide (Review) -- Adults (Review No.1)
pdf, 297kb -
Glibenclamide (Review) -- Adults (Review No.2)
pdf, 95kb -
Histamine-1 receptor antagonists (Review) -- Adults and Children (Review No.1)
pdf, 91kb -
Histamine-1 receptor antagonists (Review) -- Adults and Children (Review No.2)
pdf, 107kb -
Human normal immunoglobulin (Additional dosage) -- Adults and Children (Review No.1)
pdf, 307kb -
Human normal immunoglobulin (Additional dosage) -- Adults and Children (Review No.2)
pdf, 140kb -
Human normal immunoglobulin (Additional dosage) -- Adults and Children (Review No.3)
pdf, 93kb -
Hydromorphone (Addition) -- Children (Review No.1)
pdf, 125kb -
Hydromorphone (Addition) -- Children (Review No.2)
pdf, 291kb -
Imatinib (Addition) (Review No.1)
pdf, 111kb -
Imatinib (Addition) (Review No.2)
pdf, 101kb -
Isoniazid + pyridoxine + sulfamethoxazole + trimethoprim (Addition) (Review No.1)
pdf, 310kb
K to O
-
Ketorolac (Addition) -- Adults (Review No.1)
pdf, 100kb -
Ketorolac (Addition) -- Adults (Review No.2)
pdf, 293kb -
Ketotifen (Addition) -- Adults and Children (Review No.1)
pdf, 89kb -
Ketotifen (Addition) -- Adults and Children (Review No.2)
pdf, 296kb -
Lamivudine + nevirapine + zidovudine (New formulation) -- Children (Review No.1)
pdf, 447kb -
Lamivudine + stavudine (New formulation) -- Children (Review No.1)
pdf, 444kb -
Lamivudine + tenofovir disoproxil fumarate (Addition) -- Adults (Review No.1)
pdf, 443kb -
Lamivudine + zidovudine (New formulation) -- Children (Review No.1)
pdf, 449kb -
Latanoprost (Addition) -- Adults (Review No.1)
pdf, 126kb -
Latanoprost (Addition) -- Adults (Review No.2)
pdf, 292kb -
Misoprostol (Deletion) for PPH prevention -- Adults (Review No.1)
pdf, 141kb -
Misoprostol (Deletion) for PPH prevention -- Adults (Review No.2)
pdf, 92kb -
Misoprostol (Deletion) for PPH prevention -- Adults (Review No.3)
pdf, 93kb -
Misoprostol (New indication) -- Adults (Review No.1)
pdf, 140kb -
Misoprostol (New indication) -- Adults (Review No.2)
pdf, 119kb -
Misoprostol (New indication) -- Adults (Review No.3)
pdf, 100kb -
Montelukast (Addition) -- Children (Review No.1)
pdf, 137kb -
Montelukast (Addition) -- Children (Review No.2)
pdf, 290kb -
Morphine (New formulation) -- Children (Review No.1)
pdf, 371kb -
Morphine (New formulation) -- Children (Review No.2)
pdf, 110kb -
Naproxen (Addition) -- Adults (Review No.1)
pdf, 294kb -
Naproxen (Addition) -- Adults (Review No.2)
pdf, 122kb -
Nevirapine (New formulation) -- Children (Review No.1)
pdf, 449kb -
Nifurtimox + eflornithine (Addition) -- Children (Review No.1)
pdf, 444kb -
Nifurtimox + eflornithine (Addition) -- Children (Review No.2)
pdf, 97kb -
Ofloxacin (Addition) -- Adults and Children (Review No.1)
pdf, 91kb -
Ofloxacin (Addition) -- Adults and Children (Review No.2)
pdf, 291kb -
Oral hypoglycemics (Review) -- Adults (Review No.1)
pdf, 293kb -
Oral hypoglycemics (Review) -- Adults (Review No.2)
pdf, 112kb -
Oseltamivir (Deletion) -- Adults and Children (Review No.1)
pdf, 96kb -
Oseltamivir (Deletion) -- Adults and Children (Review No.2)
pdf, 152kb -
Oxycodone (Addition) -- Children (Review No.1)
pdf, 291kb -
Oxycodone (Addition) -- Children (Review No.2)
pdf, 110kb
P to Z
-
Palliative care (New section) -- Children (Review No.1)
pdf, 81kb -
Palliative care (New section) -- Children (Review No.2)
pdf, 283kb -
Palliative care (New section) -- Children (Review No.3)
pdf, 94kb -
Palliative care (New section) -- Children (Review No.4)
pdf, 287kb -
Palliative care (Review) -- Adults (Review No.2)
pdf, 139kb -
Pegylated interferon (Addition) -- Adults (Review No.1)
pdf, 101kb -
Pegylated interferon (Addition) -- Adults (Review No.2)
pdf, 103kb -
Risperidone (Addition) -- Adults (Review No.1)
pdf, 105kb -
Risperidone (Addition) -- Adults (Review No.2)
pdf, 308kb -
Second-line antituberculosis medicines (Review) -- Children (Review No.1)
pdf, 139kb -
Second-line antituberculosis medicines (Review) -- Children (Review No.2)
pdf, 101kb -
Spironolactone (New indication) -- Adults (Review No.1)
pdf, 99kb -
Spironolactone (New indication) -- Adults (Review No.2)
pdf, 104kb -
Statins (Review) -- Children (Review No.1)
pdf, 96kb -
Streptomycin (To be moved to complementary list) -- Children (Review No.1)
pdf, 86kb -
Streptomycin (To be moved to complementary list) -- Children (Review No.2)
pdf, 88kb -
Trastuzumab (Addition) -- Adults (Review No.1)
pdf, 139kb -
Trastuzumab (Addition) -- Adults (Review No.2)
pdf, 108kb -
Trastuzumab (Addition) -- Adults (Review No.3)
pdf, 96kb -
Whole blood and red blood cells (Addition) -- Adults and Children (Review No.1)
pdf, 156kb -
Whole blood and red blood cells (Addition) -- Adults and Children (Review No.2)
pdf, 173kb -
Whole blood and red blood cells (Addition) -- Adults and Children (Review No.3)
pdf, 104kb
Contact: emlsecretariat@who.int
Medicine Access and Rational Use (MAR)
20 Avenue Appia
CH-1211 Geneva 27